Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30397711 | 1.00 | FABP4 (0.98) | FABP4FABP3 | |
| SCHEMBL6684978 | 0.99 | FABP4 (1.00) | FABP4FABP3 | |
| SCHEMBL31554286 | 0.89 | FABP4 (0.86) | FABP4FABP3 | |
| SCHEMBL6688429 | 0.88 | FABP4 (0.80) | FABP4FABP3 | |
| SCHEMBL6691388 | 0.86 | FABP4 (1.00) | FABP4FABP3 | |
| SCHEMBL6691421 | 0.85 | FABP3 (1.00) | FABP4FABP3 | |
| SCHEMBL6686076 | 0.84 | FABP4 (1.00) | FABP4FABP3 | |
| SCHEMBL6686046 | 0.84 | FABP3 (0.77) | FABP4FABP3 | |
| SCHEMBL6691448 | 0.83 | FABP3 (0.87) | FABP4FABP3 | |
| SCHEMBL6684042 | 0.83 | FABP4 (1.00) | FABP4FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | claimed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | claimed |
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | claimed |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | CRESCENTA BIOSCIENCES (US) | 2024-11-12 | — | — | US | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
| US-20140363522-A1 | Compositions and Methods for Treating and/or Preventing Cancer by Inhibiting Fatty Acid Binding Proteins | NIH - DEITR | 2014-12-11 | — | — | US | disclosed |
| US-8748470-B2 | Methods for treating ovarian cancer by inhibiting fatty acid binding proteins | THE UNIVERSITY OF CHICAGO (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120289570-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CANCER BY INHIBITING FATTY ACID BINDING PROTEINS | NIH | 2012-11-15 | — | — | US | disclosed |
| WO-2004063156-A1 | NOVEL INDOLE DERIVATES AS FABP-4 INHIBITORS | BIOVITRUM AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP3 4/4885 |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | FABP1, FABP5, FABP4 | FABP4 3/4885FABP3 4/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.